Tuesday, May 14, 2024
Tuesday, May 14, 2024
HomeTagsTranscode

Tag: transcode

-Advertisement-

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to extra successfully treating most cancers utilizing...

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to extra successfully treating most cancers utilizing...

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Examine with Lead Therapeutic Candidate, TTX-MC138

Evidence of Drug Accumulation in Metastatic LesionsBOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to...
- Advertisement -

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to...

TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer

BOSTON, June 22, 2023 (WORLD NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology business dedicated to better dealing with cancer utilizing...
-Advertisement-

Must read

-Advertisement-